General Information of Drug (ID: DMF93RQ)

Drug Name
INS-37217 Drug Info
Synonyms
Denufosol tetrasodium; DCp4U; INS 37217; INS37217; Up4dC; Denufosol tetrasodium (USAN); Uridine 5'-(pentahydrogen tetraphosphate), P'''-5'-ester with 2'-deoxycytidine, tetrasodium salt; Tetrasodium [[(3S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Phase 2 [1]
Cross-matching ID
PubChem CID
10219163
CAS Number
CAS 318250-11-2
TTD Drug ID
DMF93RQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting P2Y purinoceptor 2 (P2RY2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diquafosol DM64QG9 Dry eye disease 9E1Z Phase 3 [2]
INS 316 DMTHMEI Lung cancer 2C25.0 Discontinued in Phase 3 [3]
PSB-0963 DMBDVJ1 Discovery agent N.A. Investigative [4]
RB 2 DMCEFUW Discovery agent N.A. Investigative [5]
UTPgammaS DMKLB4O Discovery agent N.A. Investigative [6]
Acid blue 25 DMCU6XV Discovery agent N.A. Investigative [4]
5BrUTP DMEVRH4 Discovery agent N.A. Investigative [6]
2-thioUTP DMJZ5V0 Discovery agent N.A. Investigative [7]
SB-416 DMJW72O Discovery agent N.A. Investigative [5]
MDT-006 DMSF4UI Constipation DD91.1 Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2Y purinoceptor 2 (P2RY2) TTOZHQC P2RY2_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1737).
2 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
3 Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol. 2001 Aug;32(2):122-8.
4 Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
5 Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7.
6 Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27.
7 Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 324).